CA2106860A1 - Organosulphur compounds useful for the treatment of glaucoma - Google Patents

Organosulphur compounds useful for the treatment of glaucoma

Info

Publication number: CA2106860A1
Authority: CA; Canada
Prior art keywords: compound; acm; derivative; salt; absent
Prior art date: 1991-03-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002106860A

Other languages

English (en)

French (fr)

Inventor

Kailash K. Gauri

Stig Aasmul-Olsen

Fred Widmer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

CARLBIOTECH Ltd AS

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-25

Filing date

1992-03-25

Publication date

1992-09-26

1992-03-25 Application filed by Individual filed Critical Individual

1992-09-26 Publication of CA2106860A1 publication Critical patent/CA2106860A1/en

Status Abandoned legal-status Critical Current

Links

208000010412 Glaucoma Diseases 0.000 title claims abstract description 26
150000002898 organic sulfur compounds Chemical class 0.000 title claims abstract description 15
150000001875 compounds Chemical class 0.000 claims abstract description 63
206010020772 Hypertension Diseases 0.000 claims abstract description 16
238000000034 method Methods 0.000 claims abstract description 9
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
108090000765 processed proteins & peptides Chemical group 0.000 claims description 52
235000001014 amino acid Nutrition 0.000 claims description 21
150000001413 amino acids Chemical group 0.000 claims description 21
230000004410 intraocular pressure Effects 0.000 claims description 21
-1 benzamidomethyl Chemical group 0.000 claims description 19
125000000217 alkyl group Chemical group 0.000 claims description 18
230000001384 anti-glaucoma Effects 0.000 claims description 15
125000003710 aryl alkyl group Chemical group 0.000 claims description 14
125000003118 aryl group Chemical group 0.000 claims description 13
125000000753 cycloalkyl group Chemical group 0.000 claims description 12
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
229910052736 halogen Inorganic materials 0.000 claims description 11
150000002367 halogens Chemical group 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 7
239000005864 Sulphur Substances 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 6
125000004122 cyclic group Chemical group 0.000 claims description 6
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
125000000539 amino acid group Chemical group 0.000 claims description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
125000004475 heteroaralkyl group Chemical group 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
125000003147 glycosyl group Chemical group 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
230000004962 physiological condition Effects 0.000 claims description 2
241000965481 Darksidea alpha Species 0.000 claims 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 1
101150009274 nhr-1 gene Proteins 0.000 claims 1
230000000694 effects Effects 0.000 description 48
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
229910001868 water Inorganic materials 0.000 description 22
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
229940024606 amino acid Drugs 0.000 description 21
241000283973 Oryctolagus cuniculus Species 0.000 description 20
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
239000000203 mixture Substances 0.000 description 19
239000000243 solution Substances 0.000 description 19
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
102000004196 processed proteins & peptides Human genes 0.000 description 16
239000003814 drug Substances 0.000 description 15
239000000047 product Substances 0.000 description 14
229940079593 drug Drugs 0.000 description 13
230000003042 antagnostic effect Effects 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
239000000843 powder Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
235000018417 cysteine Nutrition 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
239000000126 substance Substances 0.000 description 7
DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
108010016626 Dipeptides Proteins 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000008859 change Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
239000006196 drop Substances 0.000 description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical group C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 4
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 4
101800001288 Atrial natriuretic factor Proteins 0.000 description 4
102400001282 Atrial natriuretic peptide Human genes 0.000 description 4
101800001890 Atrial natriuretic peptide Proteins 0.000 description 4
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 4
238000010171 animal model Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000003921 oil Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
229960001416 pilocarpine Drugs 0.000 description 4
238000004007 reversed phase HPLC Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
229960004605 timolol Drugs 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
239000005541 ACE inhibitor Substances 0.000 description 3
102000003846 Carbonic anhydrases Human genes 0.000 description 3
108090000209 Carbonic anhydrases Proteins 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000014171 Milk Proteins Human genes 0.000 description 3
108010011756 Milk Proteins Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
239000000674 adrenergic antagonist Substances 0.000 description 3
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
239000000030 antiglaucoma agent Substances 0.000 description 3
239000002220 antihypertensive agent Substances 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001713 cholinergic effect Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
150000001945 cysteines Chemical class 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000011068 loading method Methods 0.000 description 3
235000021239 milk protein Nutrition 0.000 description 3
238000011555 rabbit model Methods 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000013643 reference control Substances 0.000 description 3
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
SUSPMXBDNAADFK-SECBINFHSA-N (2r)-3-(acetamidomethylsulfanyl)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(=O)NCSC(C)(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SUSPMXBDNAADFK-SECBINFHSA-N 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
OONBGFHNQVSUBF-KBIXCLLPSA-N Ile-Gln-Cys Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(O)=O OONBGFHNQVSUBF-KBIXCLLPSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
125000004181 carboxyalkyl group Chemical group 0.000 description 2
238000013461 design Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000001631 hypertensive effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
230000004044 response Effects 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
210000001585 trabecular meshwork Anatomy 0.000 description 2
239000003643 water by type Substances 0.000 description 2
QFQYGJMNIDGZSG-YFKPBYRVSA-N (2r)-3-(acetamidomethylsulfanyl)-2-azaniumylpropanoate Chemical compound CC(=O)NCSC[C@H]([NH3+])C([O-])=O QFQYGJMNIDGZSG-YFKPBYRVSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
RSHSGVSFTNITAE-UHFFFAOYSA-N 2-(2-oxoethenylsulfanyl)ethenone Chemical compound O=C=CSC=C=O RSHSGVSFTNITAE-UHFFFAOYSA-N 0.000 description 1
125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
241001514645 Agonis Species 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
SBUKLPSBNFWJCU-UHFFFAOYSA-N ClIBr Chemical compound ClIBr SBUKLPSBNFWJCU-UHFFFAOYSA-N 0.000 description 1
150000008574 D-amino acids Chemical group 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
208000035620 Eye penetration Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
108010009736 Protein Hydrolysates Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
229920002807 Thiomer Polymers 0.000 description 1
102400000160 Thymopentin Human genes 0.000 description 1
101800001703 Thymopentin Proteins 0.000 description 1
WPSXZFTVLIAPCN-WDSKDSINSA-N Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O WPSXZFTVLIAPCN-WDSKDSINSA-N 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
230000000397 acetylating effect Effects 0.000 description 1
238000007171 acid catalysis Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000012045 crude solution Substances 0.000 description 1
229960003067 cystine Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229960004132 diethyl ether Drugs 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
229940005501 dopaminergic agent Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004406 elevated intraocular pressure Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
230000000622 irritating effect Effects 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000003547 miosis Effects 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
231100000299 mutagenicity Toxicity 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000013642 negative control Substances 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
229910000069 nitrogen hydride Inorganic materials 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
210000001747 pupil Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000012264 purified product Substances 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
210000003786 sclera Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036299 sexual function Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 description 1
229960004517 thymopentin Drugs 0.000 description 1
125000005425 toluyl group Chemical group 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000008733 trauma Effects 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Peptides Or Proteins (AREA)

CA002106860A 1991-03-25 1992-03-25 Organosulphur compounds useful for the treatment of glaucoma Abandoned CA2106860A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK0531/91		1991-03-25
DK91531A DK53191D0 (da)	1991-03-25	1991-03-25	Organosvovlforbindelse og farmaceutisk praeparat indeholdende en saadan forbindelse

Publications (1)

Publication Number	Publication Date
CA2106860A1 true CA2106860A1 (en)	1992-09-26

Family

ID=8094601

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002106860A Abandoned CA2106860A1 (en)	1991-03-25	1992-03-25	Organosulphur compounds useful for the treatment of glaucoma

Country Status (7)

Country	Link
EP (1)	EP0577690A1 (da)
JP (1)	JPH06505988A (da)
AU (1)	AU1455992A (da)
CA (1)	CA2106860A1 (da)
DK (1)	DK53191D0 (da)
IE (1)	IE920940A1 (da)
WO (1)	WO1992016550A1 (da)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2261926C3 (de) *	1972-12-18	1978-11-30	Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt	Verfahren zur Herstellung von DL-Methionyl-DL-methionin
US4024286A (en) *	1976-05-17	1977-05-17	Miles Laboratories, Inc.	Fortification of foodstuffs with C-terminal amino acid substituted methionine dipeptides
US4491541A (en) *	1982-11-10	1985-01-01	Farmitalia Carlo Erba	Peptides
IE58407B1 (en) *	1984-04-13	1993-09-22	Akzo Nv	Peptides
US4885293A (en) *	1984-09-24	1989-12-05	Schering Corporation	Antiglaucoma agents
US4585587A (en) *	1984-10-19	1986-04-29	Northwestern University	Antigenic peptide compounds
GB8430255D0 (en) *	1984-11-30	1985-01-09	Erba Farmitalia	Biologically active oligopeptides
ES2039402T3 (es) *	1986-10-24	1993-10-01	Pfrimmer Kabi Gmbh & Co. Kg	Empleo de peptidos n,n'-bis-l-aminoacido-l-cistina en preparados de aminoacidos para alimentacion oral y parenteral.
GB8626539D0 (en) *	1986-11-06	1986-12-10	Nycomed As	Peptide compounds
DK72587D0 (da) *	1987-02-13	1987-02-13	Carlsberg Biotechnology Ltd	Fremgangsmaade til enzymatisk fremstilling af dipeptider
DK163435C (da) *	1988-08-12	1992-07-20	Carlsberg Biotechnology Ltd	Fremgangsmaade til enzymatisk fremstilling af dipeptider og derivater deraf
US5102871A (en) *	1989-04-24	1992-04-07	Kyowa Hakko Kogyo Co., Ltd.	Nutrient composition
DK167813B1 (da) *	1989-12-07	1993-12-20	Carlbiotech Ltd As	Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
HU206372B (en) *	1990-09-03	1992-10-28	Richter Gedeon Vegyeszet	Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same

1991
- 1991-03-25 DK DK91531A patent/DK53191D0/da not_active Application Discontinuation
1992
- 1992-03-25 WO PCT/DK1992/000094 patent/WO1992016550A1/en not_active Ceased
- 1992-03-25 EP EP92907708A patent/EP0577690A1/en not_active Withdrawn
- 1992-03-25 IE IE094092A patent/IE920940A1/en not_active Application Discontinuation
- 1992-03-25 CA CA002106860A patent/CA2106860A1/en not_active Abandoned
- 1992-03-25 AU AU14559/92A patent/AU1455992A/en not_active Abandoned
- 1992-03-25 JP JP4507120A patent/JPH06505988A/ja active Pending

Also Published As

Publication number	Publication date
DK53191D0 (da)	1991-03-25
WO1992016550A1 (en)	1992-10-01
EP0577690A1 (en)	1994-01-12
AU1455992A (en)	1992-10-21
JPH06505988A (ja)	1994-07-07
IE920940A1 (en)	1992-10-07

Legal Events

Date	Code	Title	Description
1996-09-25	FZDE	Dead

Publication	Publication Date	Title
US5411942A (en)	1995-05-02	Peptide derivative, pharmaceutical preparation containing it and method for treatment of glaucoma
US6147051A (en)	2000-11-14	Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
US7795222B2 (en)	2010-09-14	Methods for treating a corneal disorder and promoting skin wound healing
ES2624451T3 (es)	2017-07-14	Ligandos de melanocortina estabilizados
WO1995030687A1 (de)	1995-11-16	Neurokinin (tachykinin)-antagonisten
JP2000507617A (ja)	2000-06-20	ヘプタペプチドオキシトシン類似体
US5464821A (en)	1995-11-07	Small peptidic compounds useful for the treatment of glaucoma
ES2268730T3 (es)	2007-03-16	Composiciones farmacologicas oftalmicas.
US5393740A (en)	1995-02-28	Neurotensin Hexapeptides
AU677324B2 (en)	1997-04-17	Motilin-like polypeptides with gastrointestinal motor stimulating activity
HRP20000265A2 (en)	2000-12-31	Methods and compositions for treating rheumatoid arthritis
US6228841B1 (en)	2001-05-08	Peptide derivatives
JP2003231695A (ja)	2003-08-19	新規ペプチドおよびその医薬用途
WO1992016550A1 (en)	1992-10-01	Organosulphur compounds useful for the treatment of glaucoma
AU636427C (en)	1993-10-14	Peptide derivative, process for the preparation thereof, pharmaceutical preparation containing it and method for treatment of glaucoma
JPH10130163A (ja)	1998-05-19	アルツハイマー病の治療および予防用医薬の製造のためのブラジキニン拮抗薬の使用
JPH06321987A (ja)	1994-11-22	ペプチド誘導体及びその用途
JPH0717999A (ja)	1995-01-20	ペプチド誘導体及びその用途
JPH0641193A (ja)	1994-02-15	ペプチド誘導体およびその用途